The phase 2 study will assess the efficacy of AMG 337 based on Objective Response Rate (ORR) in subjects with advanced or metastatic solid tumors that overexpress MET, as determined by quantitative proteomics with mass spectrometry. The study will be conducted using Simon's two-stage optimal design. The null hypothesis of Simon's two-stage design states that the ORR will be ≤ 10% (poor response) and will be tested against a one-sided alternative.